About Cognoa
Cognoa is an early childhood development and pediatric behavioral health company dedicated to enabling earlier and more equitable access to care that improves the lives and outcomes of children and families. The company has developed Canvas Dx, the first and only FDA-authorized diagnostic solution designed to equip clinicians to diagnose or rule out autism in children ages 1.5 to 6 years—within days, not months or years. Using responsible AI and a whole-child data approach, Cognoa addresses the critical gap in pediatric developmental health where most children with autism aren't diagnosed until after age 4, with many underserved children missed altogether. The company's remote, digital evaluation platform overcomes long distances to scarce specialty centers, provides a faster path to next steps for all children, and uses an objective, data-driven approach that alleviates prevalent biases in diagnoses. Canvas Dx has been developed over years of testing and clinical validation with results published in peer-reviewed journals. Cognoa's technology actively seeks diverse data and trains AI to represent and account for differences in gender, race, ethnicity, and socio-economic backgrounds. The company's whole-child data approach facilitates a robust pipeline for pediatric developmental and behavioral health, including multidimensional feature evaluation, tracking, and accessible therapies. Canvas Dx is now reimbursed by Highmark Insurance and has launched the first state Medicaid program coverage in Wyoming.
Mission & Story
Mission
We are determined to change that. With our whole-child approach and responsible AI, we fortify the diagnosis of developmental concerns at the earliest and most opportune times. Our approach delivers an informed, rapid, and universally accessible path to care that saves precious time and gives children and their families the power of knowledge and the ability to realize their most fulfilling lives.
Founding Story
Foundational research began at Harvard Medical School's Center for Biomedical Informatics, where Cognoa's founder, Dr. Dennis Wall PhD, was on faculty. Early research focused on addressing the crisis of late diagnosis for children with autism and exploring machine learning as a foundation for an accurate, efficient, objective, and user-friendly diagnostic solution.
Clinical Focus
Medical conditions and clinical areas addressed by Cognoa.
Who It Serves
Milestones & Awards
Recent Milestones
First state Medicaid program coverage launched in Wyoming (September 2024). Highmark Insurance reimbursement approved. FDA authorization achieved for Canvas Dx as first and only AI-powered autism diagnostic for ages 1.5-6 years.
Awards & Recognition
First and only FDA authorized diagnostic solution for autism in children ages 1.5 to 6 years
Key Partnerships
Social & Media
Latest Updates
‘Setting a Precedent’: Cognoa Earns Medicaid Coverage for Early-Autism Diagnosis Tool
Using AI and ML to Predict Autism Spectrum Disorder
Cognoa Clinical
Cognoa’s AI child autism diagnostic gains Medicaid coverage in Wyoming
How Technology is Improving the Autism Landscape: Dr. Sharief Taraman on “What We Don’t Know with Dr. Tracy.”
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.